Form 4: Amicus Therapeutics CEO Bradley Campbell Executes Stock Option and Sells Shares

Amicus Therapeutics' CEO, Bradley Campbell, exercised stock options and sold shares on May 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On May 1, 2024, Bradley L Campbell, the President and CEO of Amicus Therapeutics, exercised stock options to acquire 7,500 shares of common stock at a price of $8.61 per share.
• Simultaneously, Campbell sold 7,500 shares of common stock at a weighted average price of $10.0698 per share, with individual transaction prices ranging from $10.00 to $10.13.
• Following these transactions, Campbell directly owns 886,654 shares of Amicus Therapeutics common stock and 52,500 stock options.
• The transactions were executed under a Rule 10b5-1 trading plan adopted on August 23, 2023.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the document simply reports stock transactions by an executive under a pre-arranged plan. There is no indication of positive or negative implications for the company.

Industry Context

Executive stock transactions are common and closely monitored, especially in the pharmaceutical industry. Rule 10b5-1 plans are frequently used to allow insiders to trade company stock without being accused of acting on non-public information.

Comparison to Industry Standards

• Executive compensation packages often include stock options as incentives.
• The use of Rule 10b5-1 trading plans is a standard practice among corporate executives to avoid accusations of insider trading.
• Comparing Campbell's transactions to those of executives at similar-sized biotech companies (e.g., BioMarin, Sarepta Therapeutics) would provide context on the scale and frequency of such activities.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership.
• The transactions do not appear to have a direct impact on employees, customers, suppliers, or creditors.

Key Dates